Published in Cancer Weekly, September 11th, 2007
Clavis Pharma has initiated a Phase II combination study of ELACYT(TM) and Nexavar(TM) (sorafenib) in previously treated malignant melanoma patients. This is an important development, and the first clinical trial where ELACYT is used in combination with another cancer drug. In the second quarter, the ELACYT Clinical Phase II study in metastatic colorectal cancer has progressed according to plan, with patient recruitment ongoing at three centres in the UK.
The work with ELACYT in blood cancers has been...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.